On January 14, 2026 Samsung Epis Holdings (KRX: 0126Z0) reported corporate progress and updates at the 44th J.P. Morgan Healthcare Conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"2026 is a monumental year for us, as we enter into a new chapter for our company. Today, we are announcing six additional candidates in our biosimilar pipeline, including vedolizumab and dupilumab. We are making great progress to secure 20 biosimilars in our portfolio by 2030," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. "We also received the investigational new drug application (IND) clearance for the first novel therapeutic candidate developed by Samsung Bioepis, and plan to advance our clinical program this year. As we broaden our portfolio beyond biosimilars, we will continue our development efforts in antibody-drug conjugates (ADCs), leveraging our innovative research and development platform to expand viable treatment options for patients with unmet needs."

Samsung Bioepis Biosimilar Updates

Samsung Bioepis currently has 11 biosimilars for 10 unique biological molecules approved and launched in more than 40 countries.1 The company has pembrolizumab biosimilar undergoing Phase 1 and 3 clinical studies, and plans to secure 20 biosimilars in its portfolio by 2030.
The new pipeline will include dupilumab, guselkumab, ixekizumab, fam-trastuzumab deruxtecan-nxki, vedolizumab, and ocrelizumab.
Novel Therapeutics Updates

In December 2025, the FDA has cleared the IND Application for SBE303. SBE303 is Samsung Bioepis’ first novel ADC engineered to bind to Nectin-4, an adhesion protein that is specifically expressed in tumor cells, including urothelial cancer, lung cancer, and breast cancer.2 The Phase 1 first-in-human clinical trial, aiming to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of SBE303 in participants with advanced refractory solid tumors, is set to begin this year.
Samsung Bioepis plans to have one novel therapeutic candidate enter into clinical study every year.
Epis NexLab, the new subsidiary under Samsung Epis Holdings, has launched a project to develop a peptide-based drug delivery platform.
Samsung Bioepis Biosimilars Portfolio

Code Name (Brand Name3)

Non-proprietary Name

Reference Product

Status4

SB5

(IMRALDI, HADLIMA, ADALLOCE)

Adalimumab

Humira

Launch

SB4

(BENEPALI, BRENZYS, ETOLOCE)

Etanercept

Enbrel

Launch

SB2

(FLIXABI, RENFLEXIS, REMALOCE)

Infliximab

Remicade

Launch

SB3

(ONTRUZANT, SAMFENET)

Trastuzumab

Herceptin

Launch

SB8

(AYBINTIO)

Bevacizumab

Avastin

Launch

SB11

(BYOOVIZ, AMELIVU)

Ranibizumab

Lucentis

Launch

SB12

(EPYSQLI)

Eculizumab

Soliris

Launch

SB15

(OPUVIZ, AFILIVU)

Aflibercept

Eylea

Launch

SB16

(OBODENCE, OSPOMYV)

Denosumab

Prolia

Launch

SB16

(XBRYK)

Denosumab

Xgeva

Launch

SB17

(PYZCHIVA, EPYZTEK)

Ustekinumab

Stelara

Launch

SB27

Pembrolizumab

Keytruda

Phase 1 and 3

Samsung Bioepis Biosimilar Candidates in Early Stage Development

Non-proprietary Name

Reference Product

Dupilumab

Dupixent

Guselkumab

Tremfya

Ixekizumab

Taltz

Vedolizumab

Entyvio

Ocrelizumab

Ocrevus

Fam-trastuzumab deruxtecan-nxki

Enhertu

(Press release, Samsung Epis Holdings, JAN 14, 2026, View Source [SID1234662050])